Deflazacort: A glucocorticoid with few metabolic adverse effects but important immunosuppressive activity

Advances in Therapy

Volumn 24, Issue 5, 2007, Pages 1052-1060

  Gonzalez Perez, Oscar ^a,b   Luquin, Sonia ^a   Garcia Estrada, Joaquin ^a   Ramos Remus, Cesar ^c  

^a UNIVERSITY OF GUADALAJARA   (Mexico)

^b UNIVERSIDAD DE COLIMA   (Mexico)

^c INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Glucocorticoids; Immunosuppression; Nonsteroidal anti inflammatory drugs; Opportunistic disease; Sepsis

Indexed keywords

DEFLAZACORT; GLUCOCORTICOID; PREDNISOLONE; PREDNISOLONE DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; BIOEQUIVALENCE; CALCIUM METABOLISM; DRUG ACTIVITY; DRUG APPROVAL; DRUG EFFECT; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DUCHENNE MUSCULAR DYSTROPHY; FOOD AND DRUG ADMINISTRATION; GLUCOSE METABOLISM; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; NERVE CELL; NONHUMAN; OPPORTUNISTIC INFECTION; PERCEPTION DEAFNESS; RHEUMATOID ARTHRITIS; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; URETER STONE;

ANTI-INFLAMMATORY AGENTS; AUTOIMMUNE DISEASES; CALCIUM; GLUCOSE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; OPPORTUNISTIC INFECTIONS; PREGNENEDIONES;

EID: 37249083012     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02877711     Document Type: Article

References (56)

1. Coirini H, Flores D, Vega MC, Gonzalez Deniselle MC, De Nicola AF. Binding of the anti-inflammatory steroid DFZ to glucocorticoid receptors in brain and peripheral tissues: in vivo and in vitro studies. J Steroid Biochem Mol Biol. 1994;49:43-49.
2. Martinelli E, Ferrari P, Ripamonti A, Tuan G, Perazzi A, Assandri A. Metabolism of deflazacort in the rat, dog and man. Drug Metab Dispos. 1979;7:335-339.
3. Assandri A, Ferrari P, Perazzi A, Ripamonti A, Tuan G, Zerilli L. Disposition and metabolism of a new steroidal anti-inflammatory agent, deflazacort, in cynomolgus monkeys. Xenobiotica. 1983;13:185-196.
4. Di Munno O, Mazzantini M, Milani S, Pasero G. Clinical equivalence between deflazacort oral drops and tablets in active rheumatoid arthritis. Clin Rheumatol. 1999;18:140-144.
5. Saag KG, Criswell LA, Sems KM, Nettleman MD, Kolluri S. Low-dose corticosteroids in rheumatoid arthritis: a meta-analysis of their moderate-term effectiveness. Arthritis Rheum. 1996;39:1818-1825.
6. Ferraris JR, Pasqualini T, Legal S, et al. Effect of deflazacort versus methylprednisone on growth, body composition, lipid profile, and bone mass after renal transplantation. The Deflazacort Study Group. Pediatr Nephrol. 2000;14:682-688.
7. Tosca MA, Cosentino C, Pallestrini E, et al. Medical treatment reverses cytokine pattern in allergic and nonallergic chronic rhinosinusitis in asthmatic children. Pediatr Allergy Immunol. 2003;14:238-241.
8. Markham A, Bryson HM. Deflazacort: a review of its pharmacological properties and therapeutic efficacy. Drugs. 1995;50:317-333.
9. Campbell C, Jacob P. Deflazacort for the treatment of Duchenne dystrophy: a systematic review. BMC Neurol. 2003;3:7.
10. Biggar WD, Harris VA, Eliasoph L, Alman B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord. 2006;16:249-255.
11. Balaban B, Matthews DJ, Clayton GH, Carry T. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect. Am J Phys Med Rehabil. 2005;84:843-850.
12. Moxley RT III, Ashwal S, Pandya S, et al. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2005;64:13-20.
13. García Callejo FJ, Corts J, de Paula Vernetta C, Laporta P, Ramírez Sabio J, Marco Algarra J. Cormobidity of sensorineural hearing loss and other autoimmune diseases: usefulness of laboratory tests [in Spanish]. Acta Otorrinolaringol Esp. 2006;57:28-33.
14. Porpiglia F, Destefanis P, Fiori C, Fontana D. Effectiveness of nifedipine and deflazacort in the management of distal ureter stones. Urology. 2000;56:579-582.
15. Dellabella M, Milanese G, Muzzonigro G. Medical-expulsive therapy for distal ureterolithiasis: randomized prospective study on role of corticosteroids used in combination with tamsulosin - simplified treatment regimen and health-related quality of life. Urology. 2005;66:712-715.
16. Nathansohn G, Pasqualucci CR, Radaelli P, Schiatti P, Selva D, Winters G. Steroids possessing nitrogen atoms. V. Some pharmacological and chemico-physical aspects of a new class of active corticoids: [17alpha,16alpha-d]-oxazolino-steroids. Steroids. 1969;13:365-381.
17. Buttgereit F, da Silva JA, Boers M, et al. Standardized nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis. 2002;61:718-722.
18. Herve JC. Non-genomic effects of steroid hormones on membrane channels. Mini Rev Med Chem. 2002;2:411-417.
19. Barnes PJ. Molecular mechanisms and cellular effects of glucocorticosteroids. Immunol Allergy Clin North Am. 2005;25:451-468.
20. Cato AC, Schacke H, Sterry W, Asadullah K. The glucocorticoid receptor as target for classic and novel anti-inflammatory therapy. Curr Drug Targets Inflamm Allergy. 2004;3:347-353.
21. Wehling M. Specific, nongenomic actions of steroid hormones. Annu Rev Physiol. 1997;59:365-393.
22. Wehling M, Losel R. Non-genomic steroid hormone effects: membrane or intracellular receptors? J Steroid Biochem Mol Biol. 2006;102:180-183.
23. Cantrill HL, Waltman SR, Palmberg PF, Zink HA, Becker B. In vitro determination of relative corticosteroid potency. J Clin Endocrinol Metab. 1975;40:1073-1077.
24. Mager DE, Moledina N, Jusko WJ. Relative immunosuppressive potency of therapeutic corticosteroids measured by whole blood lymphocyte proliferation. J Pharm Sci. 2003;92:1521-1525.
25. Mullol J, Xaubet A, Lopez E, Roca-Ferrer J, Picado C. Comparative study of the effects of different glucocorticosteroids on eosinophil survival primed by cultured epithelial cell supernatants obtained from nasal mucosa and nasal polyps. Thorax. 1995;50:270-274.
26. Langhoff E, Ladefoged J. Relative immunosuppressive potency of various corticosteroids measured in vitro. Eur J Clin Pharmacol. 1983;25:459-462.
27. Angeli A, Bisbocci D, Melo F, Frairia R, Gaidano GP. Relative competition of corticosterone, cortisol, cortisone, 11-deoxycortisol and prednisolone with (1,2-3H)-cortisol in various protein-binding radioassay systems. Clin Chim Acta. 1975;61:279-286.
28. Downie WW, Dixon JS, Lowe JR, Rhind VM, Leatham PA, Pickup ME. Adrenocortical suppression by synthetic corticosteroid drugs: a comparative study of prednisolone and betamethasone. Br J Clin Pharmacol. 1978;6:397-399.
29. Wilson AM, Coutie WJ, Sims EJ, Lipworth BJ. The skin vasoconstrictor assay does not correlate significantly to airway or systemic responsiveness to inhaled budesonide in asthmatic patients. Eur J Clin Pharmacol. 2003;58:643-647.
30. Lo Cascio V. Deflazacort and bone mass. Clin Exp Rheumatol. 2000;18(suppl 21):69-73.
31. Dubois EF, Derks MG, Zwinderman AH, Dekhuijzen PN, Van Boxtel CJ, Schweitzer DH. Distinct actions of prednisolone and dexamethasone towards osteocalcin and eosinophilic cationic protein in assumed clinically equivalent doses: a study in healthy men. Eur J Clin Pharmacol. 2003;58:733-737.
32. Dubois EF, Wagemans MF, Verdouw BC, et al. Lack of relationships between cumulative methylprednisolone dose and bone mineral density in healthy men and postmenopausal women with chronic low back pain. Clin Rheumatol. 2003;22:12-17.
33. Dubois EF, Derks MG, Schweitzer DH, Zwinderman AH, Dekhuijzen PN, van Boxtel CJ. Pharmacokinetic/pharmacodynamic modelling of effects of dexamethasone and prednisolone in combination with endogenous cortisol on lymphocyte counts and systemic markers of bone turnover and inflammation in healthy and asthmatic men. Eur J Clin Pharmacol. 2004;60:315-328.
34. Hahn TJ, Halstead LR, Strates B, Imbimbo B, Baran DT. Comparison of subacute effects of oxazacort and prednisone on mineral metabolism in man. Calcif Tissue Int. 1980;31:109-115.
35. Gennari C, Imbimbo B, Montagnani M, Bernini M, Nardi P, Avioli LV. Effects of prednisone and deflazacort on mineral metabolism and parathyroid hormone activity in humans. Calcif Tissue Int. 1984;36:245-252.
36. Cacoub P, Chemlal K, Khalifa P, et al. Deflazacort versus prednisone in patients with giant cell arteritis: effects on bone mass loss. J Rheumatol. 2001;28:2474-2479.
37. Pagano G, Lombardi A, Ferraris GM, Imbimbo B, Cavallo Perin P. Acute effect of prednisone and deflazacort on glucose tolerance in prediabetic subjects. Eur J Clin Pharmacol. 1982;22:469-471.
38. Gonzalez-Castaneda RE, Castellanos-Alvarado EA, Flores-Marquez MR, et al. Deflazacort induced stronger immunosuppression than expected. Clin Rheumatol. 2007;26:935-940.
39. Padial A, Posadas S, Alvarez J, et al. Nonimmediate reactions to systemic corticosteroids suggest an immunological mechanism. Allergy. 2005;60:665-670.
40. Bonifati MD, Ruzza G, Bonometto P, et al. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle Nerve. 2000;23:1344-1347.
41. Hodson EM, Knight JF, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev. 2005;(1):CD001533.
42. Broyer M, Terzi F, Lehnert A, Gagnadoux MF, Guest G, Niaudet P. A controlled study of deflazacort in the treatment of idiopathic nephrotic syndrome. Pediatr Nephrol. 1997;11:418-422.
43. Ferraris JR, Pasqualini T, Alonso G, et al. Effects of deflazacort vs methylprednisone: a randomized study in kidney transplant patients. Pediatr Nephrol. 2007;22:734-741.
44. Langhoff E, Olgaard K. In vitro immunosuppressive potency of deflazacort, a new bone-sparing corticosteroid on T lymphocytes, NK and K cells. Br J Clin Pharmacol. 1986;21:125-129.
45. Langhoff E, Olgaard K, Ladefoged J. The immunosuppressive potency in vitro of physiological and synthetic steroids on lymphocyte cultures. Int J Immunopharmacol. 1987;9:469-473.
46. Luzzani F, Glasser A. Differential binding in vitro to glucocorticoid receptors of deflazacort and prednisolone. Eur J Pharmacol. 1981;76:427-430.
47. Luzzani F, Barone D, Galliani G, Glasser A. Ex vivo binding to glucocorticoid receptors in the thymus of the adrenalectomized rat. Eur J Pharmacol. 1983;87:61-66.
48. Luzzani F, Barone D, Galliani G, Schiatti P, Glasser A. Ex vivo binding to thymic glucocorticoid receptors: correlation with biological responses. Adv Exp Med Biol. 1984;171:313-320.
49. Omote M, Sakai K, Mizusawa H. Acute effects of deflazacort and its metabolite 21-desacetyl-deflazacort on allergic reactions. Arzneimittelforschung. 1994;44:149-153.
50. Schiatti P, Selva D, Barone D, Restelli A, Glasser A. Antiinflammatory activity and other pharmacological properties of 11 beta, 21-dihydroxy-2′- methyl-5′ beta H-pregna-1,4-dieno[17,16-d]-oxazole-3,20-dione-21-acetate (Deflazacort). Arzneimittelforschung. 1980;30:1543-1549.
51. Scudeletti M, Pende D, Barabino A, Imbimbo B, Grifoni V, Indiveri F. Effect of single oral doses of prednisone and deflazacort on human lymphocyte distribution and functions: analysis with monoclonal antibodies. Adv Exp Med Biol. 1984;171:335-344.
52. Ramos-Remus C, Gonzalez-Castaneda RE, Gonzalez-Perez O, Luquin S, Garcia-Estrada J. Prednisone induces cognitive dysfunction, neuronal degeneration, and reactive gliosis in rats. J Investig Med. 2002;50:458-464.
53. Symons AL, Henry AC, Chang S, Daley TJ, Harbrow DJ, Joseph BK. The effect of glucocorticosteroid treatment on dentine formation in the Lewis rat: a histological study. Growth Factors. 2000;18:157-167.
54. Baixauli Rubio A, Rodríguez Górriz E, Campos Fernández C, Calvo Catalá J, García Vicente S. Rare opportunistic disease in a patient treated with immunosuppressive therapy for rheumatoid arthritis [in Spanish]. An Med Interna. 2003;20:276-277.
55. Navarro Llanos A, Elizalde Eguinoa J, Boto de los Bueys B, Pujol de la Llave E. Toxic epidermal necrolysis in a patient treated with high doses of deflazacort [in Spanish]. Med Clin (Barc). 1996;106:599.
56. Gomez CM, Higuero NC, Moral de Gregorio A, et al. Urticaria-angioedema by deflazacort. Allergy. 2002;57:370-371.